|
Condensed Consolidated Financial Statement Detail (Details)
|
3 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | 1 Months Ended | 3 Months Ended | 3 Months Ended | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Mar. 31, 2014
USD ($)
|
Mar. 31, 2013
USD ($)
|
Dec. 31, 2013
USD ($)
|
Mar. 31, 2012
USD ($)
|
Feb. 28, 2010
Five year warrants issued in February 2010 [Member]
USD ($)
|
Mar. 31, 2014
Five year warrants issued in February 2010 [Member]
USD ($)
|
Dec. 31, 2013
Five year warrants issued in February 2010 [Member]
USD ($)
|
Feb. 28, 2010
Five year warrants issued in February 2010 [Member]
|
Mar. 31, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
|
Mar. 31, 2014
Five year warrants issued in March 2012 [Member]
USD ($)
|
Mar. 31, 2014
Five year warrants issued in March 2012 [Member]
|
Dec. 31, 2013
Five year warrants issued in March 2012 [Member]
USD ($)
|
Mar. 31, 2012
Five year warrants issued in March 2012 [Member]
|
Jun. 30, 2009
Warrants issued to private investors [Member]
USD ($)
|
Mar. 31, 2014
Warrants issued to private investors [Member]
USD ($)
|
Jun. 30, 2009
Warrants issued to private investors [Member]
|
Mar. 31, 2014
Options Contract [Member]
USD ($)
Contract
|
Mar. 31, 2013
Options Contract [Member]
USD ($)
|
Mar. 31, 2014
Options Contract [Member]
EUR (€)
|
Mar. 31, 2014
Option Contract 1 [Member]
EUR (€)
|
Mar. 31, 2014
Option Contract 2 [Member]
EUR (€)
|
Mar. 31, 2014
Demand Deposits [Member]
USD ($)
|
Dec. 31, 2013
Demand Deposits [Member]
USD ($)
|
Mar. 31, 2014
Money Market Funds [Member]
USD ($)
|
Dec. 31, 2013
Money Market Funds [Member]
USD ($)
|
Mar. 31, 2014
Previously Reported [Member]
|
Mar. 31, 2014
Common stock options and restricted stock units [Member]
|
Mar. 31, 2013
Common stock options and restricted stock units [Member]
|
Mar. 31, 2014
Warrants for common stock [Member]
|
Mar. 31, 2013
Warrants for common stock [Member]
|
||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||||||||||||||||||||||||||||||
| Antidilutive securities excluded from computation of earnings per share (in shares) | 7,642,000 | 22,635,000 | 5,732,000 | 6,459,000 | 1,910,000 | 16,176,000 | |||||||||||||||||||||||||||
| Numerator [Abstract] | |||||||||||||||||||||||||||||||||
| Net loss originally reported | $ (4,687,000) | $ (24,887,000) | |||||||||||||||||||||||||||||||
| Correction - removal of revaluation of contingent warrant liabilities | (19,534,000) | ||||||||||||||||||||||||||||||||
| Numerator for use in diluted loss per share of common stock - restated | (24,221,000) | ||||||||||||||||||||||||||||||||
| Denominator [Abstract] | |||||||||||||||||||||||||||||||||
| Weighted average shares outstanding used for diluted net loss per share of common stock originally reported | 115,524,000 | 82,595,000 | 106,158,000 | ||||||||||||||||||||||||||||||
| Correction - effect of dilutive warrants | 9,366,000 | ||||||||||||||||||||||||||||||||
| Denominator for use in diluted loss per share of common stock - restated | 115,524,000 | 82,595,000 | 106,158,000 | ||||||||||||||||||||||||||||||
| Cash and Cash Equivalents [Line Items] | |||||||||||||||||||||||||||||||||
| Cash equivalents | 10,100,000 | 18,900,000 | 63,600,000 | 82,800,000 | |||||||||||||||||||||||||||||
| Short-term Investments [Abstract] | |||||||||||||||||||||||||||||||||
| Short-term investments, U.S. treasury securities | 19,996,000 | 19,990,000 | [1] | ||||||||||||||||||||||||||||||
| Derivative [Line Items] | |||||||||||||||||||||||||||||||||
| Notional amount of derivative liability | 15,000,000 | ||||||||||||||||||||||||||||||||
| Number of foreign exchange option contracts | 2 | ||||||||||||||||||||||||||||||||
| Derivative, amount of hedged item | 1,500,000 | 15,000,000 | |||||||||||||||||||||||||||||||
| Derivative, premiums | 1,500,000 | ||||||||||||||||||||||||||||||||
| Derivative fair value | 200,000 | ||||||||||||||||||||||||||||||||
| Derivative, loss | 100,000 | 200,000 | |||||||||||||||||||||||||||||||
| Accrued liabilities [Abstract] | |||||||||||||||||||||||||||||||||
| Accrued payroll and other benefits | 2,401,000 | 3,009,000 | |||||||||||||||||||||||||||||||
| Accrued management incentive compensation | 1,050,000 | 4,386,000 | |||||||||||||||||||||||||||||||
| Other | 1,444,000 | 2,539,000 | |||||||||||||||||||||||||||||||
| Total | 4,895,000 | 9,934,000 | [1] | ||||||||||||||||||||||||||||||
| Class of Warrant or Right [Line Items] | |||||||||||||||||||||||||||||||||
| Warrants outstanding (in shares) | 1,260,000 | 12,109,418 | 14,834,577 | 347,826 | |||||||||||||||||||||||||||||
| Exercise price (in dollars per share) | $ 1.76 | $ 10.50 | $ 1.76 | $ 19.50 | |||||||||||||||||||||||||||||
| Fair value of warrant liability | 1,200,000 | 46,600,000 | 68,700,000 | 700,000 | |||||||||||||||||||||||||||||
| Gain (loss) on revaluation of warrant liability | 500,000 | 19,500,000 | |||||||||||||||||||||||||||||||
| Warrant Term | 5 years | 5 years | 5 years | ||||||||||||||||||||||||||||||
| Reclassification of warrant liability to equity | $ 2,500,000 | ||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||